INTRODUCTION
The mouse pancreas forms as an outpocketing from the embryonic gut beginning at day 10 of gestation (elO) [1] . Later, the attachment of the pancreatic buds to the gut narrows, forming the pancreatic duct and the cells lining the duct differentiate into exocrine and endocrine tissues [1] . The cells in the dorsal and ventral gut wall that give rise to the pancreatic anlage can be distinguished already at day e8 by expression of the homeodomain protein IPF-I [2] . This protein was originally cloned as an insulin gene transcription factor (insulin promoter factor-i) but its early expression indicates that it serves an additional function in early pancreatic development. This was recently demonstrated convincingly as mice homozygous for an IPF-1 gene disrupted by homologous recombination completely failed to develop the pancreas [3] .
fl-Cell-specific expression of the rat insulin 1 gene has been found to be dependent on cis-acting elements located in the 5'-flanking sequence [4, 5] . A number of discrete cis-acting elements have been defined by mutational analysis [6] . Two sites (El and E2) (throughout this paper we use the newly adopted nomenclature for insulin gene cis-elements [7] ), containing eight base pairs of identical sequence (-110 to -103 and -238 to -231, respectively) which include a so-called E-box (CANNTG), are critical for a high expression level. These sites bind the factor, insulin enhancer factor-I (IEF-1) [8, 9] . IEF-I is a dimer composed ofeither one ofthe ubiquitous helix-loop-helix 6F-GLU) expresses STF-I in all cells prior to insulin gene activation induced by in vivo culture. In contrast, a mouse a-cell line (aTCl) exclusively expressed IPF-I in a small subset of insulin-producing cells while an insulin-negative subclone (aTC1.9) was negative for IPF-1. In transfection experiments using aTC1.9 cells STF-I activated a rat insulin 1 reporter gene dependent not only on both STF-I-binding sites, but also on the El-binding site for the helix-loop-helix factor IEF-1. However, the endogenous mouse insulin genes remained inactive in these cells. These results suggest that the insulin promoter acquires its very high, yet cell-specific, activity at least partly through the action of IPF-i/STF-1. This action is dependent on helixloop-helix factors bound to the El element.
(HLH) proteins, Pan-I or Pan-2, in conjunction with an isletspecific HLH protein [10] [11] [12] [13] [14] .
Additionally, two 'TAAT'-motif-containing sites have been implicated in the fl-cell-specific activity of the rat insulin 1 promoter [2, 10, 15] . These two sites, the A3/A4 element (-222 to -208) and the Al element (-81 to -74) both bind the homeodomain protein IPF-i/STF-i/IDX-1 [2, 15, 16] ; additionally, the A3/A4 element binds insulin enhancer factor-2 (IEF-2) [10] . The cloning of mouse IPF-I and the rat homologue, named alternatively somatostatin transactivating factor-I (STF-1) or islet duodenum homeobox factor-I (IDX-1) (in the remaining part of this paper we will refer to the mouse protein by the name IPF-I and the rat protein by the name STF-1), showed that they belong to a new class of homeodomain proteins [2, 16, 17] , distinct from Isl-I and lmx-1, two LIM-homeodomain proteins which in recombinant form are able to bind to the A3/A4 element [18, 19] . We and others have recently reported that STF-I is capable of binding to and transactivating the human insulin gene and, furthermore, appears to be involved in the glucose-regulated transcription of the insulin gene [20, 21] . STF-1 is also capable of activating a transfected rat insulin 1 promoter in synergy with Pan-I when introduced into HeLa cells [15] .
The expression pattern of IPF-1 in the adult pancreas is still unresolved. Although found only in the islets within the pancreas, one report describes IPF-1 expression as restricted to the ,-cells [2] , whereas two other reports describe IPF-1 expression in the majority of islet fl-cells but also in approximately 20 0 of the Abbreviations used: CAT, chloramphenicol acetyltransferase; FITC, fluorescein isothiocyanate; HLH, helix-loop-helix; IAPP, islet amyloid polypeptide; IDX-1, islet duodenum homeobox factor-1; IEF-1, insulin enhancer factor-1; IPF-1, insulin promoter factor-1; STF-1, somatostatin transactivating factor-1; SV40, simian virus 40.
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Figure 1 Confocal laser scanning and convential micrograph images of monolayers of newborn rat islet cells Confocal laser scanning images are shown of monolayers of newborn rat islet cells double stained with antiserum to STF-1 followed by FITC-conjugated secondary antibody (a-c), and with monoclonal antibodies to insulin (a), somatostatin (b), or glucagon (c) followed by Texas Red-conjugated secondary antibody. (d) A conventional micrograph of the same culture used in (b) was stained with antiserum to STF-1 followed by FITC-conjugated secondary antibody and a monoclonal antibody to somatostatin followed by Texas Red-conjugated secondary antibody. Bars, 10 ,um.
8-cells and 1-2 % of the a-cells. Therefore the aim of the present study was (a) to elucidate the cell specificity of IPF-l /STF-l in both primary and transformed islet cell cultures, and (b) to investigate its mechanism of action on insulin gene transcription.
MATERIALS AND METHODS
Cell lines and nuclear extract preparations NHI-6F-GLU (previously NHI-6F-Primary), a glucagon-producing rat cell line carrying a silent human insulin gene [22] , and NHI-6F-INS (previously NHI-6F-28), an insulin-producing cell line derived by in vivo culture of NHI-6F-GLU with high levels of insulin expression in early passages [22, 23] , were grown in RPMI 1640 medium supplemented with 10 % fetal calf serum (Gibco, BRL), 2 mM L-glutamine, penicillin (100 units/ml) and streptomycin (100 ,ug/ml) (Gibco, BRL). aTCl, a transgenically derived glucagon-producing a-cell line [24] , aTCl.9, a subclone of aTCl [25] , and pTC3, a transgenically derived insulin producing ,-cell line [26] , were grown in Dulbecco's modified Eagle's medium (DMEM) with the same supplements as used for RPMI 1640.
Nuclear extracts were prepared from these cells as described [27] .
Plasmids, transfections, and analysis of gene expression A Rat I-CAT reporter construct (pIns.CAT) containing 346 bp of the rat insulin 1 gene promoter as well as block mutants of this reporter (S7-, S8-, S10-, S20-, and S22-CAT) have all been described previously [6] . The PlM2 mutant of pIns.CAT has been described [2] . Rat I1-CAT was constructed by ligating a 745 bp BamHI-HindIII fragment from RIPTag [28] , containing 660 bp of rat insulin 2 promoter sequences, and a 1.6 kb HindIII-BamHI fragment from pSV2-CAT [29] , containing chloramphenicol acetyltransferase (CAT) gene coding sequence and simian virus 40 (SV40) poly(A) and splice site, into BamHIdigested pUC18. Transfections were by the calcium-phosphate co-precipitation method [29] , using 15,ug of reporter plasmid and 5 #g of an RSV-luciferase expression plasmid as internal control. Luciferase activities were determined (Luciferase Assay System, Promega). CAT assays were performed as described [29] after normalization to luciferase activity. Co-transfections were done either with 1 /ug of a CMV-STF-1 expression vector [17] or with 1 ,ug of the control vector pcDNAI-Neo (In Vitrogen, Abingdon, U.K.) containing a cytomegalovirus promoter without insert.
Antisera and immunochemistry
The anti-STF-I serum has been described [15] , as has the anti-IPF-1 serum [2] . Insulin-, glucagon-, and somatostatin-antisera have previously been described [30] . Cells were seeded in 8-well chamber slides (Nunc, Glostrup, Denmark) prior to immunocytochemistry which was performed as described [23] .
Newborn rat islets were isolated as described previously [311. Growth hormone-promoted monolayers of newborn rat islets were prepared and cultured on microscope slides (Nunc, Glostrup, Denmark) as described previously [31] . After 4 weeks of culture the monolayer islet cells were fixed in 1 % neutral paraformaldehyde for at least 24 h. Primary antibodies to islet hormones (insulin, glucagon and somatostatin) were combined with an antiserum to STF-I in double-staining experiments by indirect immunofluorescence with species-specific secondary antibodies labelled with fluorescein isothiocyanate (FITC) or Texas Red [32] . The stainings were examined with a Multiprobe 2001 inverted confocal laser scan microscope system (Molecular Dynamics, Stockholm, Sweden) equipped with an argon-krypton laser and a 100 x, n.a. [22, 23] . Double staining for STF-I and insulin did not reveal any obvious correlation between intensity of STF-I staining and insulin expression as intense STF-I immunoreactivity could be found in cells not expressing insulin (Figure 2 ). Thus immunocytochemistry confirms that STF-I is equally abundant in NHI-6F-GLU and NHI-6F-INS cells, as previously demonstrated in band shift analysis [20] . (Figure 3d ). Double staining for glucagon and IPF-1 showed that all glucagon-producing cells were negative for IPF-1 (Figure 3h ). Thus, a perfect correlation between insulin production and IPF-l expression was observed, strengthening the notion of IPF-1 as a transcription factor required for insulin expression.
The transcriptional activity of insulin 5'-flanking DNA is higher in NHI-6F-INS than in NHI-6F-GLU cells We Figure 4) . When comparing the activity of the two promoters in NHI-6F-INS cells we found that the rat insulin 1 enhancer/promoter had about 5-fold higher activity than the insulin 2 enhancer/promoter ( Figure 4 ).
Activation of the rat Insulin 1 gene by STF-1 is dependent on an intact El, but not E2, HLH-factor binding site
The different distribution of STF-1/IPF-l suggests that introducing STF-I to aTCl.9 cells should activate co-transfected insulin reporters whereas the same experiment performed in NHI-6F-GLU cells would not be expected to activate insulin reporters to the same degree due to the already high expression of STF-1. To test the effect of expressing STF-1 cDNA in aTCl .9 and NHI-6F-GLU cells upon rat insulin 1 promoter activity we co-transfected pIns.CAT with either an STF-1 expression vector or a control vector. After normalization to a firefly luciferase internal control,'CAT activities were determined. As seen in Figure 5 , cd-transfection of STF-1 leads to only a moderate (1.7-fold) increase in CAT activity when assayed in NHI-6F-GLU cells but to a 3-to 5-fold increase when assayed in aTCl.9 cells. We then asked which cis-elements were required for STF-1-mediated transactivation in aTCl.9 cells. In addition to determining the importance of the 'TAAT'-motif-containing Al and A3/A4 elements we also wanted to examine the involvement of IEF-1, a heterodimeric HLH-protein binding to the El and E2 sites in the rat insulin 1 promoter which is present in aTCI cells and its subclones aTCI.6 and aTCI.9 ([10,33] ; P. Serup, unpublished work). We reasoned that aTCl.9 cells would offer a unique system in which to examine the possible cooperation between STF-1 (provided exogenously) and IEF-l (provided endogenously). By co-transfecting STF-1 with rat insulin 1 reporters containing block mutations in either of the abovementioned cis-elements we found that the A3/A4 binding site was required for activation as only 1.4-fold activation of the S20 mutant construct was seen ( Figure 5 ). The three mutations affecting the Al site yielded slightly different results. The S7 and S8 block mutants were activated to the same degree as the wildtype construct. These mutants, however, coincidentally create new potential binding sites for STF-I right next to the original site and thus the activation could be mediated by these. To test this we next assayed the P1M2 mutant which only affects the central nucleotides in the 'TAAT' motif. The STF-l-mediated activity of this mutant is clearly reduced, although not to the same extent as seen with the A3/A4 mutant. When examining activation of the El and E2 mutants (S10 and S22, respectively) we found that the El site was absolutely required for basal activity as well as for activation by STF-1, indicating that binding of the HLH-factor IEF-I to El is required for the activity of STF-I on the insulin promoter. In contrast, mutation of the E2 site significantly lowered the basal activity but showed approximately 10-fold activation by STF-1.
STF-1 does not activate the endogenous insulin genes in aTC1.9 cells If STF-l/IPF-l was the sole determinant for lack of the insulin gene expression in a-cells, as suggested by the co-expression of insulin and IPF-l in the aTCl subpopulation, then expression of STF-l in aTC1.9 cells might activate not only transfected insulin genes 'but also the endogenous mouse insulin 1 and 2 genes. We tested this by transfecting aTCl.9 cells with the STF-I cDNA and, after 48 h, we performed double-labelling immunocytochemistry for STF-I and either insulin or glucagon. STF-1-positive cells were readily detected and often found in pairs where the cells were in contact, indicating that the transfected cells had undergone cell division. As seen in Figure 6 or, in addition to fl-cell expression, expression also in a small fraction of a-and 8-cells [15, 34, 35] . The absence of IPF-1/STF-1 in the majority of 8-cells shows that it is not strictly required for somatostatin expression, but does not exclude a possible role in the activation of somatostatin expression during the islet development.
In spite of the very low frequency of insulin-positive cells, most if not all of the pluripotent NHI-6F-GLU cells expressed STF-immunoreactivity. This might explain the high frequency of IAPP-positive cells in NHI-6F-GLU [32] . fl-Cell-specific expression of the IAPP gene is regulated by factors shared with the insulin gene; in particular, an A3/A4 binding factor (possibly IPF-l/STF-l) has been implicated in cell-specific expression of the IAPP gene [36] . Only the small subset of aTCI cells which express insulin do also express IPF-1. The perfect correlation between insulin-and IPF-1-expression in aTC1 cells suggests that IPF-I is required for insulin gene activity. Taken together the IPF-1/STF-I expression in the two glucagon-producing cell lines, however, suggests that this protein constitutes only one of several factors restricting insulin expression to the f-cell.
We find that the induction of insulin gene expression that occurs during in vivo culture [22] is reflected by increased activity of transiently transfected rat insulin 1 and 2 enhancer/promoters. As STF-I is uniformly expressed in NHI-6F-GLU cells it was not surprising that co-transfection of an STF-expression vector into these cells had only a minimal effect upon a rat insulin 1 reporter gene. The in vivo induction of insulin gene expression S20 S22
therefore cannot be explained by induction of either IPF-1 /STF-1, IEF-2 or IEF-1, which are all present in NHI-6F-GLU cells. Using aTCl.9 cells as an IPF-l/STF-1-negative background we find that rat insulin 1 gene expression could be enhanced 3-to 5-fold by co-transfection of STF-I cDNA. This is in agreement with our previous finding that human insulin gene activity can be stimulated 4-fold in acTCl cells by co-transfection of STF-1 cDNA [20] . We then used this system to assay which cis-elements were required for activation by STF-1. Activation of the Al mutant (PIM2) was clearly reduced compared with wild type, although some activation was still detectable, while activation of the A3/A4 mutant (S20) was severely reduced. This indicates that both of these elements are required for full activity of STF-1 on the insulin promoter. This is in agreement with results obtained on the rat insulin 2 promoter [34] and the human insulin promoter [20] . Early transfection experiments have indicated that the A3/A4 element by itself cannot stimulate promoter activity in insulin-producing cells when linked to a heterologous promoter but instead it is capable of augmenting expression dependent upon El and E2 sites [37] . Interestingly, we found that the El but not the E2 element was required for STF-1 activation. This suggests that STF-1-mediated activation of the rat insulin promoter is dependent on the binding of the HLHfactor IEF-I to the El site and presence of an E2 site cannot compensate for the loss of the El site. This apparent cooperativity between STF-I and IEF-I is in agreement with a recent report which finds that in HeLa cells STF-l is capable of activating the insulin promoter synergistically with one component of IEF-I namely the HLH-protein Pan-l [15] . Previous work by German and co-workers has suggested that the A3/A4 element cooperated with the E2 element in the so-called FF-mini-enhancer [36] . These data, however, were obtained with multimerized FFmini-enhancers. In contrast, our data are obtained with the complete promoter. In this context it is noteworthy that neither the rat insulin 2 nor the human insulin gene contains an E2 box capable of binding IEF-I [38] .
Introduction of STF-1 cDNA into ocTC 1.9 cells transiently did not activate the endogenous insulin genes, and glucagon expression remained unaffected. Using immunocytochemistry we readily detected the STF-1 protein properly localized to the nucleus. The failure of STF-l to activate the mouse insulin genes indicates that one or more factors in addition to IPF-I/STF-I and IEF-I are required in order to activate chromosomally located insulin genes.
